Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

10.95USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$10.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
236,105
52-wk High
$56.00
52-wk Low
$9.24

NLNK.OQ

Chart for NLNK.OQ

About

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $316.43
Shares Outstanding(Mil.): 28.90
Dividend: --
Yield (%): --

Financials

  NLNK.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -2.62 -- --
ROI: -35.33 -9.20 14.43
ROE: -36.76 -9.24 15.61

BRIEF-Newlink Genetics elected to terminate Wuxi agreement

* Determined to discontinue manufacturing operations for Algenpantucel-L and to terminate Wuxi agreement

Jun 06 2016

NewLink shares tumble as pancreatic cancer therapy fails

Shares of NewLink Genetics Corp plunged 37 percent in extended trading on Monday after the drug maker said its experimental pancreatic cancer immunotherapy did not help patients live longer in a late-stage trial.

May 09 2016

UPDATE 2-NewLink shares tumble as pancreatic cancer therapy fails

May 9 Shares of NewLink Genetics Corp plunged 37 percent in extended trading on Monday after the drug maker said its experimental pancreatic cancer immunotherapy did not help patients live longer in a late-stage trial.

May 09 2016

NewLink Genetics' pancreatic cancer therapy fails late-stage study

May 9 NewLink Genetics Corp said on Monday its experimental pancreatic cancer immunotherapy did not meet the main goal in a late-stage study.

May 09 2016

BRIEF-Newlink Genetics posts Q1 loss per share of $0.82

* Impress phase 3 top-line results now expected in Q2 of 2016

Apr 29 2016

BRIEF-Newlink Genetics awarded $21.6 million contract option for Ebola vaccine development

* Newlink Genetics awarded $21.6 million contract option by Barda for Ebola vaccine development

Apr 25 2016

BRIEF-Newlink Genetics receives $2.8 mln award from DTRA to develop a multivalent filovirus vaccine

* Receives $2.8 million award from DTRA to develop a multivalent filovirus vaccine

Apr 15 2016

NewLink Genetics says working on Zika vaccine

U.S. drug developer NewLink Genetics Corp joined the race to develop a vaccine for the Zika virus, a day after the World Health Organization declared the mosquito-borne disease an international public health emergency.

Feb 02 2016

UPDATE 1-NewLink Genetics says working on Zika vaccine

Feb 2 U.S. drug developer NewLink Genetics Corp joined the race to develop a vaccine for the Zika virus, a day after the World Health Organization declared the mosquito-borne disease an international public health emergency.

Feb 02 2016

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,702 +10.00
Pfizer Inc. (PFE.N) $36.83 --
Novartis AG (NOVN.S) CHF82.00 -0.50
Merck & Co., Inc. (MRK.N) $58.36 --
Roche Holding Ltd. (ROG.S) CHF250.00 -0.30
Roche Holding Ltd. (RO.S) CHF251.25 0.00
Abbott Laboratories (ABT.N) $43.60 --
Sanofi SA (SASY.PA) €76.70 +0.13
AstraZeneca plc (AZN.L) 4,641.50p +3.00
GlaxoSmithKline plc (GSK.L) 1,694.62p +28.00

Earnings vs. Estimates